Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

CEVEC, Yuhan ink license agreement
February 2013
SHARING OPTIONS:

COLOGNE, GermanyŚCEVEC Pharmaceuticals and Yuhan Corp. have signed a CAP-Technology license agreement enabling Yuhan to make use of CEVEC's CAP-T and CAP cell expression systems for the production and development of therapeutic proteins. CEVEC's CAP-T CAP cells, immortalized cell lines for transient and stable protein production, are non-tumor origin cell lines that allow for superior protein yields in less time.
 
 
"With Yuhan we have won one of the most prestigious Asian pharma companies as a customer. We're very pleased that Yuhan has chosen our CAP and CAP-T expression systems as a pivotal platform to develop therapeutically relevant molecules. I'm convinced that the cells will have a major impact to develop more efficient biologics and will also shorten the timeline to enter clinical phases," CEVEC CEO Wolfgang Kintzel said in a statement.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.